ARWR – Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc.ARWR
$19.56Name : Arrowhead Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $2,433,928,960.00
EPSttm : -5
Arrowhead Pharmaceuticals, Inc.
$19.56
2.84%$0.54Float Short %
8.64
Margin Of Safety %
Put/Call OI Ratio
0.56
EPS Next Q Diff
0.67
EPS Last/This Y
1.63
EPS This/Next Y
-0.58
Price
19.57
Target Price
43.42
Analyst Recom
1.71
Performance Q
-7.3
Relative Volume
0.61
Beta
0.95
Ticker: ARWR
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2024-12-19 | ARWR | 19.47 | 0.33 | 0.86 | 22782 |
| 2024-12-20 | ARWR | 19.45 | 0.34 | 1.07 | 23625 |
| 2024-12-23 | ARWR | 19.76 | 0.44 | 0.11 | 13763 |
| 2024-12-24 | ARWR | 19.63 | 0.42 | 0.32 | 14282 |
| 2024-12-26 | ARWR | 19.54 | 0.42 | 0.68 | 14361 |
| 2024-12-27 | ARWR | 18.96 | 0.44 | 0.63 | 14724 |
| 2024-12-30 | ARWR | 18.61 | 0.44 | 0.89 | 15312 |
| 2024-12-31 | ARWR | 18.81 | 0.50 | 0.49 | 16510 |
| 2025-01-02 | ARWR | 19.73 | 0.50 | 0.40 | 16628 |
| 2025-01-03 | ARWR | 19.8 | 0.49 | 0.92 | 17289 |
| 2025-01-06 | ARWR | 19.49 | 0.51 | 0.29 | 17955 |
| 2025-01-07 | ARWR | 19.67 | 0.51 | 1.19 | 18176 |
| 2025-01-08 | ARWR | 19.74 | 0.52 | 0.16 | 18415 |
| 2025-01-09 | ARWR | 19.75 | 0.52 | 0.16 | 18415 |
| 2025-01-10 | ARWR | 18.48 | 0.51 | 1.83 | 18575 |
| 2025-01-13 | ARWR | 18.89 | 0.52 | 0.13 | 19131 |
| 2025-01-14 | ARWR | 18.04 | 0.53 | 3.48 | 19016 |
| 2025-01-15 | ARWR | 18.91 | 0.55 | 0.26 | 19257 |
| 2025-01-16 | ARWR | 19.02 | 0.55 | 22.20 | 19284 |
| 2025-01-17 | ARWR | 19.56 | 0.56 | 0.05 | 19439 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2024-12-19 | ARWR | 19.49 | 43.2 | 19.5 | -3.32 |
| 2024-12-20 | ARWR | 19.47 | 43.2 | -6.4 | -3.32 |
| 2024-12-23 | ARWR | 19.75 | 43.2 | -16.8 | -3.32 |
| 2024-12-24 | ARWR | 19.63 | 42.0 | -3.6 | -3.36 |
| 2024-12-26 | ARWR | 19.53 | 42.0 | -4.2 | -3.36 |
| 2024-12-27 | ARWR | 18.96 | 42.0 | 10.9 | -3.36 |
| 2024-12-30 | ARWR | 18.62 | 42.0 | 3.9 | -3.36 |
| 2024-12-31 | ARWR | 18.84 | 42.0 | -15.2 | -3.36 |
| 2025-01-02 | ARWR | 19.67 | 42.0 | -36.8 | -3.36 |
| 2025-01-03 | ARWR | 19.78 | 42.0 | -11.7 | -3.36 |
| 2025-01-06 | ARWR | 19.50 | 42.0 | 1.8 | -3.36 |
| 2025-01-07 | ARWR | 19.66 | 42.0 | -12.6 | -3.36 |
| 2025-01-08 | ARWR | 19.75 | 42.0 | -9.9 | -3.36 |
| 2025-01-09 | ARWR | 19.75 | 42.0 | -7.4 | -3.36 |
| 2025-01-10 | ARWR | 18.48 | 42.0 | 33.2 | -3.36 |
| 2025-01-13 | ARWR | 18.89 | 42.0 | -21.1 | -3.36 |
| 2025-01-14 | ARWR | 18.05 | 42.0 | 21.3 | -3.36 |
| 2025-01-15 | ARWR | 18.91 | 42.0 | -37.8 | -3.36 |
| 2025-01-16 | ARWR | 19.02 | 42.0 | -10.4 | -3.36 |
| 2025-01-17 | ARWR | 19.57 | 41.7 | -25.7 | -3.37 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2024-12-19 | ARWR | -0.38 | -0.51 | 8.67 |
| 2024-12-20 | ARWR | -0.38 | -0.51 | 8.67 |
| 2024-12-23 | ARWR | -0.85 | -0.53 | 8.67 |
| 2024-12-24 | ARWR | -0.85 | -0.53 | 8.67 |
| 2024-12-26 | ARWR | -0.85 | -0.53 | 8.43 |
| 2024-12-27 | ARWR | -0.83 | -0.53 | 8.43 |
| 2024-12-30 | ARWR | -0.86 | -0.51 | 8.43 |
| 2024-12-31 | ARWR | -0.89 | -0.51 | 8.43 |
| 2025-01-02 | ARWR | -0.86 | -0.51 | 8.43 |
| 2025-01-03 | ARWR | -0.87 | -0.51 | 8.43 |
| 2025-01-06 | ARWR | -0.75 | -0.53 | 8.43 |
| 2025-01-07 | ARWR | -0.89 | -0.53 | 8.43 |
| 2025-01-08 | ARWR | -2.22 | -0.53 | 8.43 |
| 2025-01-09 | ARWR | -2.22 | -0.53 | 8.43 |
| 2025-01-10 | ARWR | -2.22 | -0.53 | 8.43 |
| 2025-01-13 | ARWR | -2.22 | -0.48 | 8.64 |
| 2025-01-14 | ARWR | -2.17 | -0.48 | 8.64 |
| 2025-01-15 | ARWR | -2.17 | -0.48 | 8.64 |
| 2025-01-16 | ARWR | -2.17 | -0.48 | 8.64 |
| 2025-01-17 | ARWR | -2.17 | -0.48 | 8.64 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.37
Avg. EPS Est. Current Quarter
-0.72
Avg. EPS Est. Next Quarter
-0.7
Insider Transactions
-2.17
Institutional Transactions
-0.48
Beta
0.95
Average Sales Estimate Current Quarter
62
Average Sales Estimate Next Quarter
74
Fair Value
Quality Score
12
Growth Score
25
Sentiment Score
67
Actual DrawDown %
79.1
Max Drawdown 5-Year %
-80.4
Target Price
43.42
P/E
Forward P/E
PEG
P/S
685.62
P/B
13.12
P/Free Cash Flow
EPS
-5
Average EPS Est. Cur. Y
-3.37
EPS Next Y. (Est.)
-3.95
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-16882.37
Relative Volume
0.61
Return on Equity vs Sector %
-342.4
Return on Equity vs Industry %
-329.8
EPS 1 7Days Diff
EPS 1 30Days Diff
0.29
EBIT Estimation
-25.7
Arrowhead Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 525
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.
stock quote shares ARWR – Arrowhead Pharmaceuticals, Inc. Stock Price stock today
news today ARWR – Arrowhead Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ARWR – Arrowhead Pharmaceuticals, Inc. yahoo finance google finance
stock history ARWR – Arrowhead Pharmaceuticals, Inc. invest stock market
stock prices ARWR premarket after hours
ticker ARWR fair value insiders trading